"Using Biology Of Atopic Dermatitis To Improve Therapy" - Charles Bankhead
Following the therapeutic model of psoriasis, treatment for atopic dermatitis (AD) increasingly focuses on identifying and targeting specific molecules involved in etiology and pathogenesis, experts said. The potential for applying the psoriasis model to AD did not become apparent until recently, as AD is a more complex condition, involving abnormalities in both immune response and the skin barrier, said Emma Guttman-Yassky, MD, PhD, professor of dermatology, clinical immunology and medicine, vice chair of research in the department of dermatology, and director of the Center for Excellence in Eczema in the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai, at the American Academy of Dermatology meeting. "Unlike psoriasis, AD cannot be explained by a single cytokine pathway," said Dr. Guttman-Yassky. "But the consistent cytokine axis activated across all phenotypes appears to be Th2. Thus far, dupilumab shows similar in intrinsic/extrinsic and filaggrin-positive and negative AD phenotypes."
- Emma Guttman-Yassky, MD, PhD, The Sol & Clara Professor, Dermatology, Clinical Immunology, Medicine, Vice Chair, Research, Department of Dermatology, Director, The Center for Excellence in Eczema, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai